Clinical trial
B-Receptor Signaling in Cardiomyopathy
NCT01135849 is registered in ClinicalTrials.gov with Daniel Bernstein as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- B-Receptor Signaling in Cardiomyopathy
- Lead sponsor
- Daniel Bernstein
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 30, 2008
- Completion date
- October 31, 2010
- Enrollment
- 99 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
amyloidosis, anal cancer, anemia, bone cancer, bone marrow transplant failure, breast cancer, cancer of brain and nervous system, carcinoma of the large intestine, carcinomas, cholangiocarcinoma of the extrahepatic bile duct, endocrine cancer, esophageal cancer, eye cancer, gall bladder cancer, gastric (stomach) cancer, gastrointestinal stromal tumor (gist), gastrooesophageal cancer, gynecologic cancers, head and neck cancers, hepatobiliary neoplasm, hodgkin disease, kidney (renal cell) cancer, leukemia, lung cancer, lymphoma, non-hodgkin, mesothelioma, multiple myeloma, myelodysplastic syndromes (mds), myeloproliferative disorders, neuroendocrine tumors, pancreatic cancer, prostate cancer, skin cancer, soft tissue sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional cell carcinoma of bladder